Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Overview of attention for article published in Frontiers in oncology, April 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 25 publications that cite this research output.

25

The most recent citing publications are shown below. View all 25 publications that cite this research output on Dimensions.

Efficacy and Safety of PD-1 Monoclonal Antibodies in the Treatment of Esophageal Squamous Cell Carcinoma: Systematic Review And Meta Regression

Article in Heliyon (July 2024)

Prognostic Nutritional Index as a Prognostic Indicator for the Occurrence of Postoperative Complications in Patients with Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy

Article in Cancer Management and Research (June 2024)

Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real‐world analysis

Article in Thoracic Cancer (March 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.